JP2010540547A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540547A5 JP2010540547A5 JP2010527091A JP2010527091A JP2010540547A5 JP 2010540547 A5 JP2010540547 A5 JP 2010540547A5 JP 2010527091 A JP2010527091 A JP 2010527091A JP 2010527091 A JP2010527091 A JP 2010527091A JP 2010540547 A5 JP2010540547 A5 JP 2010540547A5
- Authority
- JP
- Japan
- Prior art keywords
- aliskiren
- combination
- important
- dissolution
- fixed dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 9
- 229960004601 aliskiren Drugs 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 5
- 229940000425 combination drug Drugs 0.000 description 4
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 3
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 3
- 229960004699 valsartan Drugs 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97592507P | 2007-09-28 | 2007-09-28 | |
| US97590107P | 2007-09-28 | 2007-09-28 | |
| US97591907P | 2007-09-28 | 2007-09-28 | |
| US97590907P | 2007-09-28 | 2007-09-28 | |
| PCT/US2008/077416 WO2009045795A2 (en) | 2007-09-28 | 2008-09-24 | Galenical formulations of aliskiren and valsartan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010540547A JP2010540547A (ja) | 2010-12-24 |
| JP2010540547A5 true JP2010540547A5 (enExample) | 2012-11-01 |
Family
ID=40377183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010527091A Withdrawn JP2010540547A (ja) | 2007-09-28 | 2008-09-24 | アリスキレンおよびバルサルタンのガレヌス製剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100209480A1 (enExample) |
| EP (1) | EP2205233A2 (enExample) |
| JP (1) | JP2010540547A (enExample) |
| KR (1) | KR20100063090A (enExample) |
| CN (1) | CN101808631A (enExample) |
| AR (1) | AR066168A1 (enExample) |
| AU (1) | AU2008309058B2 (enExample) |
| BR (1) | BRPI0817442A2 (enExample) |
| CA (1) | CA2698330A1 (enExample) |
| CL (1) | CL2008002829A1 (enExample) |
| CO (1) | CO6270217A2 (enExample) |
| EC (1) | ECSP10010052A (enExample) |
| MA (1) | MA31706B1 (enExample) |
| MX (1) | MX2010003441A (enExample) |
| PE (1) | PE20090654A1 (enExample) |
| TN (1) | TN2010000135A1 (enExample) |
| TW (1) | TW200924737A (enExample) |
| WO (1) | WO2009045795A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2697229A1 (en) * | 2007-09-28 | 2009-04-02 | Novartis Ag | Galenical formulations of organic compounds |
| AR073651A1 (es) * | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| WO2010107966A1 (en) * | 2009-03-20 | 2010-09-23 | Novartis Ag | Pharmaceutical composition comprising aliskiren |
| US20120009257A1 (en) * | 2009-03-20 | 2012-01-12 | Indrajit Ghosh | Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren |
| WO2011116115A1 (en) * | 2010-03-16 | 2011-09-22 | Novartis Ag | Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing |
| TR201002256A1 (tr) * | 2010-03-24 | 2011-10-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Stabil aliskiren formülasyonları |
| CN101926793B (zh) * | 2010-08-05 | 2012-08-15 | 成都自豪药业有限公司 | 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法 |
| KR20140076621A (ko) * | 2011-10-12 | 2014-06-20 | 다우 글로벌 테크놀로지스 엘엘씨 | 사출 성형된 투여형 |
| MX2014007933A (es) * | 2011-12-26 | 2014-07-30 | Novartis Ag | Comprimidos y agentes recubiertos en seco. |
| CN103349652B (zh) * | 2013-05-11 | 2014-11-19 | 辽宁大学 | 含有四氢萘酰胺化合物或其可药用盐的高药物载荷片剂 |
| JP2023553010A (ja) | 2020-12-03 | 2023-12-20 | バテル・メモリアル・インスティテュート | 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法 |
| EP4320233A4 (en) | 2021-04-07 | 2025-08-13 | Battelle Memorial Institute | RAPID DESIGN, BUILD, TEST, AND LEARNING TECHNOLOGIES TO IDENTIFY AND USE NON-VIRAL VECTORS |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| AR048431A1 (es) * | 2004-03-17 | 2006-04-26 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| BRPI0516128A (pt) * | 2004-10-08 | 2008-08-26 | Novartis Ag | uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| CN101166523A (zh) * | 2005-04-27 | 2008-04-23 | 诺瓦提斯公司 | 治疗动脉粥样硬化的方法 |
-
2008
- 2008-09-24 CN CN200880108860A patent/CN101808631A/zh active Pending
- 2008-09-24 MX MX2010003441A patent/MX2010003441A/es not_active Application Discontinuation
- 2008-09-24 JP JP2010527091A patent/JP2010540547A/ja not_active Withdrawn
- 2008-09-24 US US12/678,877 patent/US20100209480A1/en not_active Abandoned
- 2008-09-24 PE PE2008001660A patent/PE20090654A1/es not_active Application Discontinuation
- 2008-09-24 BR BRPI0817442-3A patent/BRPI0817442A2/pt not_active IP Right Cessation
- 2008-09-24 KR KR1020107006603A patent/KR20100063090A/ko not_active Withdrawn
- 2008-09-24 CA CA2698330A patent/CA2698330A1/en not_active Abandoned
- 2008-09-24 TW TW097136690A patent/TW200924737A/zh unknown
- 2008-09-24 AR ARP080104137A patent/AR066168A1/es not_active Application Discontinuation
- 2008-09-24 CL CL2008002829A patent/CL2008002829A1/es unknown
- 2008-09-24 EP EP08835022A patent/EP2205233A2/en not_active Withdrawn
- 2008-09-24 AU AU2008309058A patent/AU2008309058B2/en not_active Ceased
- 2008-09-24 WO PCT/US2008/077416 patent/WO2009045795A2/en not_active Ceased
-
2010
- 2010-03-17 MA MA32701A patent/MA31706B1/fr unknown
- 2010-03-26 EC EC2010010052A patent/ECSP10010052A/es unknown
- 2010-03-26 TN TNP2010000135A patent/TN2010000135A1/fr unknown
- 2010-04-19 CO CO10045487A patent/CO6270217A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010540547A5 (enExample) | ||
| MX2022002952A (es) | Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluor o-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbo nil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo. | |
| JP2014005302A5 (enExample) | ||
| WO2009034541A3 (en) | Controlled release pharmaceutical dosage forms of trimetazidine | |
| JP2007302683A5 (enExample) | ||
| NZ600129A (en) | Capsule formation of pirfenidone and pharmaceutically acceptable excipients | |
| RU2009106681A (ru) | Гранулированные фармацевтические композиции | |
| JP2015515459A5 (enExample) | ||
| NO20081325L (no) | Nye doseringsformuleringer | |
| SG164375A1 (en) | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof | |
| JP2017518334A5 (enExample) | ||
| WO2003072025A3 (en) | Modified release formulations of at least one form of tramadol | |
| WO2006084474A3 (en) | A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor | |
| EA031255B1 (ru) | Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения | |
| SI2729130T1 (en) | Combined formulations of darunavir | |
| CY1115709T1 (el) | Φαρμακευτικη μορφη περιεχουσα φλουπιρτινη με ελεγχομενη αποδεσμευση της δραστικης ουσιας | |
| WO2007022255A3 (en) | Pharmaceutical formulations for sustained release | |
| JP2009541387A5 (enExample) | ||
| WO2007100382A3 (en) | Orally administrable gallium compositions and method of use | |
| RU2015138784A (ru) | Фармацевтическая композиция в виде мультичастиц, содержащая множество гранул двух видов | |
| JPWO2019004452A1 (ja) | 医薬組成物 | |
| JP2018039810A5 (enExample) | ||
| DE602006015062D1 (de) | 3-aminocarbazolverbindungen, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zu deren herstellung | |
| RU2016106336A (ru) | Противотуберкулезная композиция, содержащая рифампицин, изониазид, этамбутол и пиразинамид, и способ ее получения | |
| JP2020510073A5 (enExample) |